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EditorThe cutaneous lymphomas are a heterogeneous
groupof B-cell andT-cell non-Hodgkin lymphomas
that are considered rare cancers. Even the most
common subtype of cutaneous T-cell lymphoma,
mycosis fungoides (MF) (along with its leukemic
counterpart Se´zary syndrome [SS]), has an inci-
dence of only about 6 to 7 per million persons by
the SEER data. There has been considerable
change in the past 10 years in terms of defining
the various subtypes of cutaneous lymphoma,
developing new standards for diagnosis, classifi-
cation, staging, and response criteria, and intro-
ducing new FDA-approved treatments and a new
approach to effective management of MF/SS that
is not necessarily chemotherapy dependent. It is
important for both dermatologists and oncologists
to understand how to diagnose and manage these
patients using these advances, particularly as none
of these cutaneous lymphomas currently has a
curative treatment and all have considerable
impact on the quality of life and a potential adverse
effect on survival of affected patients.
This issue brings together the experience of not
only physician authors with direct expertise in the
management of patients with cutaneous lym-
phoma but also those who have contributed to
the recent advances in this area. Taken together,
these articles cover the evaluation, diagnostic ele-
ments from both clinical and pathologic assess-
ment, and staging/classification of all types of
B-cell and T-cell cutaneous lymphoma. The entireDermatol Clin 33 (2015) xiii
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under the CC BY-NC-ND license (http://creativecommons.spectrum of treatments utilized for MF and SS is
given in individual articles, and separate articles
on the treatment of the CD301 lymphoproliferative
disorders and cutaneous B-cell lymphoma give an
overview on these other common types of cuta-
neous lymphoma.
On behalf of my coauthors, I hope that the infor-
mation provided in this issue will accomplish
several goals, the first of which is to update physi-
cians on the advances in this area in the last
decade. Since all current treatment for cutaneous
lymphoma, regardless of subtype, is stage-based,
it is important that those initially seeing these pa-
tients are aware of the nuances involved in staging
and classification. In addition, this issue can serve
as a ready resource of all the current treatment op-
tions for cutaneous lymphoma, particularly MF,
including efficacy and safety information germane
to clinical practice. In summary, if this is accom-
plished, then the lives of those with cutaneous
lymphoma will be advanced.Elise A. Olsen, MD, FAAD
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